Fertility and Sterility
Volume 81, Issue 4 , Pages 989-995 , April 2004

Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening

  • Francisco Fábregues, M.D.

      Affiliations

    • Institut Clínic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
    • ,
  • Dolors Tàssies, M.D.

      Affiliations

    • Hemotherapy and Hemostasis Unit, Faculty of Medicine-University of Barcelona, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
    • ,
  • Juan C Reverter, M.D.

      Affiliations

    • Hemotherapy and Hemostasis Unit, Faculty of Medicine-University of Barcelona, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
    • ,
  • Francisco Carmona, M.D.

      Affiliations

    • Institut Clínic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
    • ,
  • Antonio Ordinas, M.D.

      Affiliations

    • Hemotherapy and Hemostasis Unit, Faculty of Medicine-University of Barcelona, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
    • ,
  • Juan Balasch, M.D.

      Affiliations

    • Institut Clínic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
    • Corresponding Author InformationReprint requests: Juan Balasch, M.D., Institut Clínic of Obstetrics and Gynecology, Hospital Clínic, C/Casanova 143, 08036-Barcelona, Spain (FAX: 34-93-2275454).

Received 4 June 2003 ,Revised 8 September 2003 ,Accepted 8 September 2003.

References 

  1. Pride SM, James CSJ, Yuen BH. The ovarian hyperstimulation syndrome. Semin Reprod Endocrinol. 1990;8:247–260
  2. Delvigne A, Demoulin A, Smitz J, Donnez J, Koninckx P, Dhont M, et al.  The ovarian hyperstimulation syndrome in in-vitro fertilization (a Belgian multicenter study). Hum Reprod. 1993;8:1353–1360
  3. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome—views and ideas. Hum Reprod. 1997;12:1129–1137
  4. Balasch J, Fábregues F, Arroyo V. Peripheral arterial vasodilation hypothesis (a new insight into the pathogenesis of ovarian hyperstimulation syndrome). Hum Reprod. 1998;13:2718–2730
  5. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome (a current survey). Fertil Steril. 1978;30:255–268
  6. Phillips LL, Gladstone W, van de Wiele R. Studies of the coagulation and fibrinolytic systems in hyperstimulation syndrome after administration of human gonadotrophins. J Reprod Med. 1975;14:138–143
  7. Inbar OJ, Levran D, Mashiach S, Dor J. Ischemic stroke due to induction of ovulation with clomiphene citrate and menotropins without evidence of ovarian hyperstimulation syndrome. Fertil Steril. 1994;62:1075–1076
  8. Aurousseau MH, Samama MM, Belhassen A, Herve F, Hugues JN. Risk of thromboembolism in relation to an in vitro fertilization programme (three case reports). Hum Reprod. 1995;10:94–97
  9. Aboulghar MA, Mansour RT, Serour GI, Amin YM. Moderate ovarian hyperstimulation syndrome complicated by deep cerebrovascular thrombosis. Hum Reprod. 1998;13:2088–2091
  10. Loret de Mola JR, Kiwi R, Austin C, Goldfarb JM. Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:1253–1255
  11. Lane DA, Mannuci P, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al.  Inherited thrombophilia. Part I. Thromb Haemost. 1996;76:651–661
  12. Dulitzky M, Cohen SB, Inbal A, Seidman DS, Soriano D, Lidor A, et al.  Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. Fertil Steril. 2002;77:463–467
  13. Horstkamp B, Lübke M, Kentenich H, Riess H, Buscher U, Lichtenegger W. Internal jugular vein thrombosis caused by resistance to activated protein C as a complication of ovarian hyperstimulation after in-vitro fertilization. Hum Reprod. 1996;11:280–282
  14. Hollemaert S, Wautrecht JC, Capel P, Abramowicz MJ, Englert Y, Delbaere A. Thrombosis associated with ovarian hyperstimulation syndrome in a carrier of the factor V Leiden mutation. Thromb Haemost. 1996;76:275–277
  15. Ellis MH, Nun IB, Rathaus V, Werner M, Shenkman L. Internal jugular vein thrombosis in patients with ovarian hyperstimulation syndrome. Fertil Steril. 1998;69:140–142
  16. Todros T, Carmazzi CM, Bontempo S, Gaglioti P, Donvito V, Massobrio M. Spontaneous ovarian hyperstimulation syndrome and deep vein thrombosis in pregnancy. Hum Reprod. 1999;14:2245–2248
  17. Bertina RM. The prothrombin 20210 G to A variation and thrombosis. Curr Opin Hematol. 1998;5:339–342
  18. Marchetti M, Quaglini S, Barosi G. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. Q J Med. 2001;94:365–372
  19. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome (an update review). Obstet Gynecol Surv. 1989;44:430–440
  20. Balasch J, Fábregues F, Creus M, Moreno V, Puerto B, Peñarrubia J, et al.  Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization. Hum Reprod. 1996;11:2400–2404
  21. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C (prediction of a cofactor to activated protein C). Proc Nat Acad Sci U S A. 1993;90:1004–1008
  22. Jorquera JI, Montoro JM, Fernández MA, Aznar JA, Aznar J. Modified test for activated protein X resistance. Lancet. 1994;344:1162–1163
  23. Boom R, Sol CJA, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990;28:495–503
  24. Thein SL, Walance RB. The use of synthetic oligonucleotides as specific hybridization probes in the diagnosis of genetic disorders. In:  Davis KE editors. Human genetic diseases, a practical approach. Oxford: IRL Press; 1986;p. 33–50
  25. Muñoz-Rodriguez FJ, Reverter JC, Font J, Tàssies D, Espinosa G, Cervera R, et al.  Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus. Lupus. 2002;11:730–735
  26. Poort SR, Rosendaal FR, Reitsma PH, Berina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703
  27. Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with new chromogenic substrates (S-2238 and Chromozyme TH). Thromb Res. 1977;11:549–553
  28. Bertina RM, Broekmans AW, Krommenhoek-van Es C, van Wijngaarden A. The use of a functional and immunological assay for plasma protein C in the study of the heterogenity of congenital protein C deficiency. Thromb Haemost. 1984;51:1–5
  29. Amiral J, Grosley M, Boyer-Neumann C, Marfaing-Koka A, Peynaud-Debayle E, Wolf M, et al.  New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form. Blood Coagul Fibrinolysis. 1994;5:179–186
  30. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant (an update). Thromb Haemost. 1995;74:1185–1190
  31. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies (isotype distribution and phospholipid specificity). Ann Rheum Dis. 1987;46:1–6
  32. McColl MD, Walker ID, Greer IA. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol. 1999;106:756–766
  33. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost. 2001;86:112–123
  34. Aillaud MF, Succo E, Alessi MC, Gandois JM, Gallian P, Morange P, et al.  Resistance to activated protein C—diagnostic strategy in a laboratory of hemostasis. Thromb Haemost. 1995;74:1197–1207
  35. Altés A, Souto JC, Mateo J, Borrell M, Fontcuberta J. Activated protein C resistance assay when applied in the general population. Am J Obstet Gynecol. 1997;176:358–359
  36. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril. 1999;72:646–651
  37. Aune B, Hoie KE, Oian P, Holst N, Osterud B. Does ovarian stimulation for in vitro fertilization induce a hypercoagulable state?. Hum Reprod. 1991;6:925–927
  38. Biron C, Galtier-Dereure F, Rabesandratana H, Bernard I, Aguilar-Martinez P, Schved JF, et al.  Hemostasis parameters during ovarian stimulation for in vitro fertilization (results of a prospective study). Fertil Steril. 1997;67:104–109
  39. Stewart JA, Hamilton PJ, Murdoch AP. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod. 1997;12:2167–2173
  40. Todorow S, Schricker ST, Siebzehnruebl RB, Neidhardt B, Wildt L, Lang N. Von Willebrand factor (an endothelial marker to monitor in vitro fertilization patients with ovarian hyperstimulation syndrome). Hum Reprod. 1993;8:2039–2046
  41. Balasch J, Reverter JC, Fábregues F, Tassies D, Ordinas A, Vanrell JA. Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome. Fertil Steril. 1996;66:608–613
  42. Kodama H, Takeda S, Fukuda J, Miya H, Shimizu Y, Murata M, et al.  Activation of plasma kinin system correlates with severe coagulation disorders in patients with ovarian hyperstimulation syndrome. Hum Reprod. 1997;12:891–895
  43. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173:210–213
  44. Pasi KJ, Perry DJ, Lee CA. Thromboembolism and the combined oral contraceptive pill. Lancet. 1996;345:1437
  45. Dahlbäck B. Are we ready for factor V Leiden screening?. Lancet. 1996;347:1346–1347
  46. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden (should we screen oral contraceptive users and pregnant women?). Br Med J. 1996;313:1127–1130
  47. McDonough PG. Estrogen levels and thrombophilia—an intervening variable or a confounder?. Fertil Steril. 2002;78:889–890
  48. Bellver J, Simón C, Pellicer A. Estrogen levels and thrombophilia—an intervening variable or a confounder?. Fertil Steril. 2002;78:887–888
  49. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222–1231
  50. Mushlin AI, Ruchlin HS, Callahan MA. Cost-effectiveness of diagnostic tests. Lancet. 2001;358:1353–1355
  51. Kaunitz AM. Oral contraceptive use and venous thromboembolism. Translating epidemiologic data into clinical practice. ACOG Clin Rev. 1999;4:1–12
  52. Clark P, Twaddle S, Walker ID, Scott L, Greer IA. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet. 2002;359:1919–1920

☆ Supported in part by grants from the Fondo de Investigaciones Sanitarias (FIS 96/0355, FIS 98/171, and FIS 99/148) and grant RCMN (C03/08) from the Instituto de Salud Carlos III.

PII: S0015-0282(03)03182-0

doi: 10.1016/j.fertnstert.2003.09.042

Fertility and Sterility
Volume 81, Issue 4 , Pages 989-995 , April 2004

Article Tools